Login to Your Account



Phase II/III CML Data To Support NDA

ChemGenex Merges Diabetes Spin-Off To Focus On Cancer

By Randall Osborne


Tuesday, October 30, 2007
A month after disclosing positive top-line Phase II/III data with its compound for chronic myeloid leukemia (CML), ChemGenex Pharmaceuticals Ltd. is spinning out its efforts in diabetes and obesity in favor of the cancer push. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription